X

Drug Profile

AK antiVEGF

Alternative Names: AAVAnc80-antiVEGF Vector

Latest Information Update: 05 Dec 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Akouos
Class Antineoplastics; Gene therapies; Immunotherapies
Mechanism of Action Gene transference; Vascular endothelial growth factors inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Neurilemmoma

Most Recent Events

01 Dec 2022 Akouos has been acquired by Eli Lilly and Company
15 Aug 2022 Akouos intends to submit IND application to the US FDA for Neurilemmoma in 2023
08 Feb 2022 Pharmacodynamics data from preclinical trials in neurilemmoma released by Akouos

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com